在皮疹后重新挑战拉莫特里金:系统性审查
Hannah R Riva1,2, Sabrina Zheng1, Nehaa Sohail1
1Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas.
The Journal of clinical psychiatry
|January 7, 2026
概括
在仔细管理的情况下,lamotrigine重新挑战在84%的病例中是成功的. 确认最初的皮疹不是严重的,对于安全的lamotrigine重新引入至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
- 临床药房 临床药房
背景情况:
- 皮肤的不良反应是对lamotrigine的一个担忧.
- 重新挑战决策需要仔细评估风险.
研究的目的:
- 为了确定lamotrigine的成功率,重新挑战.
- 描述皮肤反应,指导重新引入的决定.
主要方法:
- 系统审查PubMed,SCOPUS和科学网络.
- 包含了11篇文章,详细介绍了106个lamotrigine重新挑战案例.
主要成果:
- 在84%的病例中,lamotrigine重试成功发生.
- 成功的再试剂通常涉及低起始剂量 (5-12.5毫克),并逐渐定位.
- 皮肤科医生确认最初的皮疹诊断是不常见的 (3%).
结论:
- 在特定的患者中,可以安全地重新使用拉莫特里金.
- 在重新引入之前,仔细评估最初的皮疹特征是必不可少的.
- 提供了评估重新挑战适度的建议.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
880
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
880
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Therapeutic Drug Monitoring: Overview and Classification
293
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
293
Mania and Antimanic Drugs: Overview
540
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
540
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
804
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
804


